FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2779746431> ?p ?o ?g. }

• W2779746431 endingPage "302" @default.
• W2779746431 startingPage "291" @default.
• W2779746431 abstract "Prostacyclins play an important role in the management of pulmonary arterial hypertension (PAH). Intravenous prostacyclin was the first disease-specific treatment for patients with PAH. Subcutaneous and nonparenteral (oral or inhaled) formulations have subsequently become available. However, data are lacking on how these different prostacyclin formulations are being used in clinical practice.To (a) conduct retrospective analyses of a large U.S. health care claims database to describe the characteristics of patients with PAH initiating prostacyclin therapy, and (b) evaluate their treatment patterns, health care resource use, and associated costs.Truven Commercial and Medicare databases were used to define annual cohorts of adults with PAH between January 1, 2010, and October 31, 2015. These patients were identified based on claims with ICD-9-CM diagnoses indicative of PAH (codes 416.0 or 416.8) and claims for PAH-specific medications and PAH-related procedures. Patients with evidence of receiving a prostacyclin were identified, and prostacyclin use was categorized as parenteral versus nonparenteral. Health care costs were assessed alternatively employing an all-cause and PAH-related perspective.Of 13,633 adults with identified PAH, 3,006 (22.0%) received a prostacyclin during at least 1 year of the study period, and annual prevalence of prostacyclin use ranged from 19.9% to 22.6%. Across calendar years, the median age of prostacyclin users ranged from 56 to 58 years, and 71.9%-75.8% were female. Among prostacyclin users, parenteral prostacyclin use declined from 63.2% in 2010 to 46.5% in 2015, while use of nonparenteral prostacyclins increased from 39.7% to 56.2% over the same period (both P < 0.001). Few patients (2.7%-4.1%) received both parenteral and nonparenteral formulations in a given calendar year. Among patients using prostacyclins, receipt of other PAH-specific medications increased from 62.1% in 2010 to 79.2% in 2015. Comparing the 6 months preceding the first prostacyclin prescription (any formulation) to the 6 months subsequent, mean overall health care costs rose from $61,243 to $119,283, and PAH-related health care costs increased from $58,815 to $116,661, driven mainly by PAH-specific medications, spending on which increased from $15,053 to $73,705 (all P < 0.001).While overall use of prostacyclins was relatively constant from 2010 to 2015, our findings revealed a shift from parenteral to nonparenteral formulations, coupled with increased prescribing of PAH-related medications from other drug classes. Further research is needed to better understand how these changes in patterns of prostacyclin use affect levels of health care resource utilization and costs and patients' overall quality of life.This research was funded by Actelion Pharmaceuticals US, a Janssen pharmaceutical company of Johnson & Johnson. Burger has received grant funding from Actelion, Gilead Sciences, and United Therapeutics; personal fees from Actelion and Gilead Sciences; and nonfinancial support from Actelion. Pruett, Lickert, and Drake are employees of Actelion. Pruett and Lickert own shares in Actelion. Berger and Murphy are employees of Evidera, a consultancy that received payment from Actelion to conduct this research. Pruett, Lickert, Berger, and Drake contributed to study conception and participated with Burger in study design. Lickert and Murphy performed the data analyses. Burger, Pruett, Lickert, Murphy, and Drake interpreted the data. All authors participated in manuscript drafting and/or critical revision, approved the final manuscript, and agree to be accountable for all aspects of the work." @default.
• W2779746431 created "2018-01-05" @default.
• W2779746431 creator A5018840280 @default.
• W2779746431 creator A5021429186 @default.
• W2779746431 creator A5023364014 @default.
• W2779746431 creator A5035172298 @default.
• W2779746431 creator A5062733502 @default.
• W2779746431 creator A5088826060 @default.
• W2779746431 date "2018-03-01" @default.
• W2779746431 modified "2023-09-24" @default.
• W2779746431 title "Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database" @default.
• W2779746431 cites W1567116170 @default.
• W2779746431 cites W1990905820 @default.
• W2779746431 cites W1999594706 @default.
• W2779746431 cites W2003005123 @default.
• W2779746431 cites W2013814008 @default.
• W2779746431 cites W2028086898 @default.
• W2779746431 cites W2034227629 @default.
• W2779746431 cites W2035384054 @default.
• W2779746431 cites W2061326496 @default.
• W2779746431 cites W2095956343 @default.
• W2779746431 cites W2101249203 @default.
• W2779746431 cites W2120945208 @default.
• W2779746431 cites W2127994875 @default.
• W2779746431 cites W2129168200 @default.
• W2779746431 cites W2132843316 @default.
• W2779746431 cites W2135449090 @default.
• W2779746431 cites W2137127902 @default.
• W2779746431 cites W2139954704 @default.
• W2779746431 cites W2142743112 @default.
• W2779746431 cites W2154332638 @default.
• W2779746431 cites W2157947374 @default.
• W2779746431 cites W2161370807 @default.
• W2779746431 cites W2162572028 @default.
• W2779746431 cites W2166964193 @default.
• W2779746431 cites W2171240223 @default.
• W2779746431 cites W2171792567 @default.
• W2779746431 cites W2184111926 @default.
• W2779746431 cites W2233162971 @default.
• W2779746431 cites W2278696749 @default.
• W2779746431 cites W2287048942 @default.
• W2779746431 cites W2321522617 @default.
• W2779746431 cites W2409904211 @default.
• W2779746431 cites W2475225291 @default.
• W2779746431 cites W2981497584 @default.
• W2779746431 doi "https://doi.org/10.18553/jmcp.2017.17228" @default.
• W2779746431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29406840" @default.
• W2779746431 hasPublicationYear "2018" @default.
• W2779746431 type Work @default.
• W2779746431 sameAs 2779746431 @default.
• W2779746431 citedByCount "10" @default.
• W2779746431 countsByYear W27797464312018 @default.
• W2779746431 countsByYear W27797464312019 @default.
• W2779746431 countsByYear W27797464312020 @default.
• W2779746431 countsByYear W27797464312021 @default.
• W2779746431 crossrefType "journal-article" @default.
• W2779746431 hasAuthorship W2779746431A5018840280 @default.
• W2779746431 hasAuthorship W2779746431A5021429186 @default.
• W2779746431 hasAuthorship W2779746431A5023364014 @default.
• W2779746431 hasAuthorship W2779746431A5035172298 @default.
• W2779746431 hasAuthorship W2779746431A5062733502 @default.
• W2779746431 hasAuthorship W2779746431A5088826060 @default.
• W2779746431 hasBestOaLocation W27797464311 @default.
• W2779746431 hasConcept C126322002 @default.
• W2779746431 hasConcept C160735492 @default.
• W2779746431 hasConcept C162324750 @default.
• W2779746431 hasConcept C167135981 @default.
• W2779746431 hasConcept C177713679 @default.
• W2779746431 hasConcept C194828623 @default.
• W2779746431 hasConcept C2781128415 @default.
• W2779746431 hasConcept C41008148 @default.
• W2779746431 hasConcept C50522688 @default.
• W2779746431 hasConcept C71924100 @default.
• W2779746431 hasConcept C77088390 @default.
• W2779746431 hasConceptScore W2779746431C126322002 @default.
• W2779746431 hasConceptScore W2779746431C160735492 @default.
• W2779746431 hasConceptScore W2779746431C162324750 @default.
• W2779746431 hasConceptScore W2779746431C167135981 @default.
• W2779746431 hasConceptScore W2779746431C177713679 @default.
• W2779746431 hasConceptScore W2779746431C194828623 @default.
• W2779746431 hasConceptScore W2779746431C2781128415 @default.
• W2779746431 hasConceptScore W2779746431C41008148 @default.
• W2779746431 hasConceptScore W2779746431C50522688 @default.
• W2779746431 hasConceptScore W2779746431C71924100 @default.
• W2779746431 hasConceptScore W2779746431C77088390 @default.
• W2779746431 hasIssue "3" @default.
• W2779746431 hasLocation W27797464311 @default.
• W2779746431 hasLocation W27797464312 @default.
• W2779746431 hasLocation W27797464313 @default.
• W2779746431 hasOpenAccess W2779746431 @default.
• W2779746431 hasPrimaryLocation W27797464311 @default.
• W2779746431 hasRelatedWork W1972407183 @default.
• W2779746431 hasRelatedWork W2105151527 @default.
• W2779746431 hasRelatedWork W2331820588 @default.
• W2779746431 hasRelatedWork W2951130915 @default.
• W2779746431 hasRelatedWork W3009852707 @default.
• W2779746431 hasRelatedWork W3013145321 @default.
• W2779746431 hasRelatedWork W3095141535 @default.

• next